Literature DB >> 16568373

Influence of chemotherapeutic agents and cytokines on the expression of 5-fluorouracil-associated enzymes in human colon cancer cell lines.

Kaori Miyazaki1, Takeshi Shibahara, Daisuke Sato, Kazuhiko Uchida, Hideo Suzuki, Hirofumi Matsui, Akinori Yanaka, Akira Nakahara, Yasushi Matsuzaki.   

Abstract

BACKGROUND: Several studies have demonstrated that intratumoral expression of catabolizing and anabolizing enzymes for 5-fluorouracil (5-FU) is important in the response of cancers to 5-FU-based chemotherapy. We investigated the influence of other chemotherapeutic agents or cytokines, which are often administered for enhancing the efficacy of 5-FU, on the tumoral expression of 5-FU-associated enzymes, i.e., dihydropyrimidine dehydrogenase (DPD), thymidylate synthase (TS), orotate phosphoribosyl transferase (OPRT), and thymidine phosphorylase (TP).
METHODS: Human colon cancer cell lines (HT-29, Caco-2, and DLD-1) were incubated with 5-FU and with 5-FU combined with cisplatin, camptothecin, paclitaxel, mitomycin C, interferon, or TNF-related apoptosis-inducing ligand. mRNA expression of 5-FU-associated enzymes was assessed by real-time PCR. Activity of each enzyme and intracellular 5-FU accumulation after incubation with such agents were also evaluated.
RESULTS: Each agent had a synergistic effect on the cytotoxicity of 5-FU. All chemotherapeutic agents other than cytokines induced marked alteration of the mRNA expression profile of 5-FU-associated enzymes; depression of DPD, elevation of TS, and slight suppression of OPRT and TP. In accordance with mRNA expression, enzyme activity of DPD was significantly depressed by such agents. Furthermore, although 5-FU itself increased DPD mRNA expression, a mechanism considered to be related to the acquisition of 5-FU resistance, the addition of cisplatin or camptothecin significantly inhibited the 5-FU-induced elevation of DPD.
CONCLUSIONS: 5-FU-associated enzymes in colon cancer cells were greatly influenced by various chemotherapeutic agents; in particular, DPD expression was depressed. These results appear important in planning chemotherapy and also in understanding the development of adverse effects of 5-FU.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16568373     DOI: 10.1007/s00535-005-1733-6

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  7 in total

Review 1.  Thymidylate synthetase - a target enzyme in cancer chemotherapy.

Authors:  P V Danenberg
Journal:  Biochim Biophys Acta       Date:  1977-12-23

2.  Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate.

Authors:  D V Santi; C S McHenry; H Sommer
Journal:  Biochemistry       Date:  1974-01-29       Impact factor: 3.162

3.  Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin.

Authors:  C G Leichman; H J Lenz; L Leichman; K Danenberg; J Baranda; S Groshen; W Boswell; R Metzger; M Tan; P V Danenberg
Journal:  J Clin Oncol       Date:  1997-10       Impact factor: 44.544

4.  Randomized comparison of fluorouracil and leucovorin therapy versus fluorouracil, leucovorin, and cisplatin therapy in patients with advanced colorectal cancer.

Authors:  W Scheithauer; D Depisch; G Kornek; J Pidlich; H Rosen; M Karall; M Prochaska; A Ernst; C Sebesta; S Eckhardt
Journal:  Cancer       Date:  1994-03-15       Impact factor: 6.860

5.  Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival.

Authors:  H J Lenz; C G Leichman; K D Danenberg; P V Danenberg; S Groshen; H Cohen; L Laine; P Crookes; H Silberman; J Baranda; Y Garcia; J Li; L Leichman
Journal:  J Clin Oncol       Date:  1996-01       Impact factor: 44.544

6.  A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil.

Authors:  A Beck; M C Etienne; S Chéradame; J L Fischel; P Formento; N Renée; G Milano
Journal:  Eur J Cancer       Date:  1994       Impact factor: 9.162

7.  Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity.

Authors:  M C Etienne; S Chéradame; J L Fischel; P Formento; O Dassonville; N Renée; M Schneider; A Thyss; F Demard; G Milano
Journal:  J Clin Oncol       Date:  1995-07       Impact factor: 44.544

  7 in total
  2 in total

1.  Treatment of colorectal cancer using a combination of liposomal irinotecan (Irinophore C™) and 5-fluorouracil.

Authors:  Jennifer I Hare; Robert W Neijzen; Malathi Anantha; Nancy Dos Santos; Natashia Harasym; Murray S Webb; Theresa M Allen; Marcel B Bally; Dawn N Waterhouse
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

2.  Conditioned media from human macrophages of M1 phenotype attenuate the cytotoxic effect of 5‑fluorouracil on the HT‑29 colon cancer cell line.

Authors:  Alexander Hedbrant; Ann Erlandsson; Dick Delbro; Jonny Wijkander
Journal:  Int J Oncol       Date:  2014-10-07       Impact factor: 5.650

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.